Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 5Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 26Sarcoma 10Other hematologic neoplasm 5Genitourinary 5Lymphoid 4Plasma cell 3Myeloid 3Gynecologic 3Gastrointestinal 3Dermatologic 3Breast 3Endocrine 2Other solid neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 5Pheochromocytoma 4Paraganglioma 3Gastro-enteropancreatic neuroendocrine tumor 3Vipoma 2Neoplasms 2Insulinoma 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms, Cystic, Mucinous, and Serous 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Liver Neoplasms 1Hypoglycemia 1Glucagonoma 1Gastrinoma 1Diarrhea 1Carcinoma, Medullary 1Cachexia 1Adrenal Gland Neoplasms 1

Interventions

Tretinoin 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroblastoma × NET × Clear all
NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡